Literature DB >> 10354655

Lithium dosage and leukocyte counts in psychiatric patients.

L K Oyewumi1, M McKnight, Z Z Cernovsky.   

Abstract

OBJECTIVE: To evaluate differences in leukocyte counts among patients treated with either lithium alone, antipsychotic medications alone, or a combination of both.
DESIGN: Retrospective study.
SETTING: Long-stay psychiatric hospital. PATIENTS: Patients admitted between 1990 and 1993, and treated with lithium for at least 1 week and/or with antipsychotic medication for at least 2 weeks. Excluded from the study were those patients for whom complete blood counts at baseline and during therapy were not available, and those patients whose blood picture could primarily be accounted for by extraneous factors. Included in the study were 38 patients treated with lithium alone, 207 patients receiving antipsychotic medications alone, and 71 patients receiving both. OUTCOME MEASURES: Leukocyte, lymphocyte and granulocyte counts.
RESULTS: Patients treated with lithium alone had significantly higher mean leukocyte and granulocyte counts than those treated with antipsychotic medication alone (analysis of variance, p < 0.05). None of the patients receiving lithium alone showed leukopenia. The dosage of lithium was significantly correlated with leukocyte count (r = 0.25, 95% confidence interval [CI] 0.14 to 0.35, p < 0.001,) and granulocyte count (r = 0.27, 95% CI 0.16 to 0.38, p < 0.001), but not with lymphocyte count (r = 0.06, p = 0.286, 95% CI -0.05 to 0.17).
CONCLUSIONS: Lithium therapy is associated with higher leukocyte and granulocyte levels in psychiatric patients. This leukocytotic effect of lithium may be dose dependent.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10354655      PMCID: PMC1189011     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  14 in total

1.  Apparent neuroleptic malignant syndrome with clozapine and lithium.

Authors:  H G Pope; J O Cole; P T Choras; C E Fulwiler
Journal:  J Nerv Ment Dis       Date:  1986-08       Impact factor: 2.254

2.  Addition of lithium carbonate to carbamazepine: hematological and thyroid effects.

Authors:  K G Kramlinger; R M Post
Journal:  Am J Psychiatry       Date:  1990-05       Impact factor: 18.112

3.  Prevention of clozapine-induced neutropenia by pretreatment with lithium.

Authors:  P H Silverstone
Journal:  J Clin Psychopharmacol       Date:  1998-02       Impact factor: 3.153

4.  Evidence that lithium induces human granulocyte proliferation: elevated serum vitamin B 12 binding capacity in vivo and granulocyte colony proliferation in vitro.

Authors:  G Tisman; V Herbert; S Rosenblatt
Journal:  Br J Haematol       Date:  1973-06       Impact factor: 6.998

5.  Effect of lithium on granulopoiesis in culture.

Authors:  D C Morley; P R Galbraith
Journal:  Can Med Assoc J       Date:  1978-02-04       Impact factor: 8.262

6.  Lithium-induced hematologic changes in patients with bipolar affective disorder.

Authors:  M A Ozdemir; S Sofuoğlu; G Tanrikulu; F Aldanmaz; E Eşel; S Dündar
Journal:  Biol Psychiatry       Date:  1994-02-01       Impact factor: 13.382

Review 7.  Clozapine: guidelines for clinical management.

Authors:  J A Lieberman; J M Kane; C A Johns
Journal:  J Clin Psychiatry       Date:  1989-09       Impact factor: 4.384

8.  Clozapine-lithium combined treatment and agranulocytosis.

Authors:  A Valevski; I Modai; M Lahav; A Weizman
Journal:  Int Clin Psychopharmacol       Date:  1993       Impact factor: 1.659

9.  Clozapine rechallenge after an episode of 'neuroleptic malignant syndrome'.

Authors:  M Weller; J Kornhuber
Journal:  Br J Psychiatry       Date:  1992-12       Impact factor: 9.319

Review 10.  Neuroleptic malignant syndrome associated with clozapine monotherapy.

Authors:  S A Thornberg; L Ereshefsky
Journal:  Pharmacotherapy       Date:  1993 Sep-Oct       Impact factor: 4.705

View more
  1 in total

1.  Effect of antipsychotics on serum lithium levels and white blood cell counts.

Authors:  Ryo Obara; Takashi Tomita; Hidekazu Goto; Yukinao Kohda; Tadashi Yoshida; Kenzo Kudo
Journal:  Neuropsychopharmacol Rep       Date:  2021-10-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.